Blockade of growth factor receptors in ductal carcinoma <i>in situ</i> inhibits epithelial proliferation

Abstract

Proliferation in DCIS was decreased by EGFR tyrosine kinase inhibition but not by c-erbB-2 receptor blockade. ZD1839, an orally active and selective EGFR-TKI, has potential as adjuvant therapy in DCIS.